Table 3.
Association of genotypes with overall survival
| Genotype | No. of Cases | No. of Deaths |
P (LR) |
Univariate
|
Multivariate
|
||
|---|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI)* | P | ||||
| Gemcitabine metabolic gene | |||||||
| CDA C111T (T145T) | 0.210 | ||||||
| CC | 73 | 15 | 1.0 | 1.0 | |||
| CT | 65 | 19 | 1.61 (0.82–3.17) | 0.168 | 2.35 (1.11–4.97) | 0.025 | |
| TT | 15 | 2 | 0.61 (0.14–2.69) | 0.517 | 0.51 (0.11–2.31) | 0.381 | |
| CC/TT vs CT | 1.73 (0.90–3.33) | 0.101 | 2.67 (1.31–5.43) | 0.007 | |||
| dCK A9846G | 0.313 | ||||||
| GG | 51 | 13 | 1.0 | 1.0 | |||
| AG | 72 | 13 | 0.72 (0.33–1.55) | 0.396 | 1.21 (0.53–2.77) | 0.653 | |
| AA | 30 | 10 | 1.34 (0.59–3.06) | 0.487 | 1.38 (0.58–3.25) | 0.464 | |
| GG/AA vs AG | 0.64 (0.32–1.26) | 0.195 | 1.05 (0.51–2.18) | 0.889 | |||
| hCNT3 C-69T (L461L) | 0.332 | ||||||
| CC | 105 | 28 | 1.0 | 1.0 | |||
| CT | 42 | 7 | 0.58 (0.25–1.32) | 0.190 | 0.63 (0.27–1.48) | 0.288 | |
| TT | 6 | 1 | 0.47 (0.06–3.48) | 0.461 | 0.27 (0.04–2.03) | 0.202 | |
| CC vs CT/TT | 0.56 (0.23–1.23) | 0.147 | 0.54 (0.24–1.19) | 0.124 | |||
| hCNT3 A25G (T89T) | 0.081 | ||||||
| TT | 52 | 16 | 1.0 | 1.0 | |||
| CT | 67 | 10 | 0.42 (0.19–0.93) | 0.033 | 0.53 (0.22–1.27) | 0.153 | |
| CC | 34 | 10 | 0.84 (0.38–1.85) | 0.663 | 0.77 (0.34–1.78) | 0.546 | |
| TT/CC vs CT | 0.46 (0.22–0.94) | 0.034 | 0.60 (0.28–1.30) | 0.196 | |||
|
| |||||||
| DNA repair gene | |||||||
| ATM C77T | 0.224 | ||||||
| TT | 47 | 10 | 1.0 | 1.0 | |||
| TC | 81 | 17 | 1.00 (0.46–2.18) | 0.996 | 1.10 (0.49–2.44) | 0.819 | |
| CC | 25 | 9 | 1.91 (0.78–4.71) | 0.158 | 1.85 (0.71–4.81) | 0.210 | |
| TT/TC vs CC | 1.92 (0.90–4.08) | 0.091 | 1.74 (0.78–3.88) | 0.178 | |||
| ATMA61G | 0.376 | ||||||
| GG | 135 | 30 | 1.0 | 1.0 | |||
| GA | 14 | 5 | 1.93 (0.74–4.98) | 0.177 | 1.72 (0.62–4.73) | 0.297 | |
| AA | 4 | 1 | 1.35 (0.18–9.89) | 0.771 | 0.97 (0.12–7.67) | 0.976 | |
| GG/AA vs GA | 1.91 (0.74–4.93) | 0.181 | 1.72 (0.62–4.73) | 0.297 | |||
| ATR C340T | 0.326 | ||||||
| CC | 45 | 14 | 1.0 | 1.0 | |||
| CT | 73 | 16 | 0.67 (0.33–1.38) | 0.281 | 0.96 (0.46–2.03) | 0.922 | |
| TT | 35 | 6 | 0.52 (0.20–1.35) | 0.177 | 0.80 (0.30–2.14) | 0.661 | |
| CC vs CT/TT | 0.62 (0.32–1.22) | 0.166 | 0.91 (0.46–1.81) | 0.790 | |||
| TREX1 Ex14-460C>T | 0.078 | ||||||
| CC | 59 | 11 | 1.0 | 1.0 | |||
| CT | 73 | 17 | 1.29 (0.61–2.76) | 0.506 | 0.87 (0.38–1.96) | 0.732 | |
| TT | 21 | 8 | 2.69 (1.08–6.69) | 0.033 | 3.02 (1.17–7.81) | 0.023 | |
| CC/CT vs TT | 2.32 (1.06–5.09) | 0.036 | 3.28 (1.44–7.51) | 0.005 | |||
|
| |||||||
| Drug resistance gene | |||||||
| MRP2 G40A | 0.057 | ||||||
| GG | 99 | 23 | 1.0 | 1.0 | |||
| AG | 49 | 10 | 0.93 (0.44–1.95) | 0.839 | 0.92 (0.42–2.03) | 0.834 | |
| AA | 5 | 3 | 3.71 (1.11–12.4) | 0.034 | 1.80 (0.52–6.22) | 0.353 | |
| GG/AG vs AA | 3.80 (1.16–12.5) | 0.028 | 1.85 (0.55–6.22) | 0.320 | |||
| GSTP1 Ex5–24A>G | 0.216 | ||||||
| AA | 62 | 18 | 1.0 | 1.0 | |||
| AG | 74 | 13 | 0.54 (0.26–1.10) | 0.090 | 0.65 (0.31–1.36) | 0.253 | |
| GG | 17 | 5 | 0.88 (0.33–2.37) | 0.799 | 0.73 (0.25–2.14) | 0.571 | |
| AA/GG vs AG | 0.56 (0.28–1.10) | 0.091 | 0.67 (0.34–1.31) | 0.243 | |||
Abbreviations: P(LR), log-rank P; HR, hazard ratio; CI, confidence interval.
*
HR was from multivariate Cox regression model with adjustment for age, number of prior chemo lines, progression and severe toxicity.